Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | SELL | P14151 | 1/20 | 0.44 |
| ▸ | SELP | P16109 | 1/20 | 0.44 |
| ▸ | SELE | P16581 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91657 | 0.83 | SMN1; SMN2 (0.40) | ACHEALDH1A1SMN1; SMN2POLBCA2 | |
| SCHEMBL19765517 | 0.82 | CA1 (0.39) | ACHEALDH1A1SMN1; SMN2CA2TMPRSS4 | |
| SCHEMBL24114399 | 0.80 | AKT1 (0.41) | ACHEALDH1A1TMPRSS4KDM4EKMT2A | |
| SCHEMBL3910478 | 0.79 | ALDH1A1 (0.62) | ACHESELLSELPSELEALDH1A1 | |
| SCHEMBL17897742 | 0.78 | SELL (0.41) | ACHESELLSELPSELEALDH1A1 | |
| SCHEMBL30973561 | 0.78 | SELL (0.41) | ACHESELLSELPSELEALDH1A1 | |
| SCHEMBL27255621 | 0.78 | SMN1; SMN2 (0.61) | ACHESELLSELPSELEALDH1A1 | |
| SCHEMBL13550098 | 0.76 | RAPGEF4 (0.41) | ACHEALDH1A1SMN1; SMN2POLBCA2 | |
| SCHEMBL83777 | 0.74 | SMN1; SMN2 (0.34) | ALDH1A1SMN1; SMN2POLBCA2TYR | |
| SCHEMBL69718 | 0.74 | ACHE (1.00) | ACHESELLSELPSELEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130337-A1 | Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists | KING'S COLLEGE LONDON (GB) | 2021-05-06 | — | — | US | disclosed |
| US-10385044-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | KING'S COLLEGE LONDON (GB) | 2019-08-20 | — | — | US | disclosed |
| US-9994559-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | KING'S COLLEGE LONDON (GB) | 2018-06-12 | — | — | US | disclosed |
| US-9994559-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | KING'S COLLEGE LONDON (GB) | 2018-06-12 | — | — | US | disclosed |
| US-20170327489-A1 | Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists | KING'S COLLEGE LONDON (GB) | 2017-11-16 | — | — | US | disclosed |
| US-20170327489-A1 | Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists | KING'S COLLEGE LONDON (GB) | 2017-11-16 | — | — | US | disclosed |
| WO-2016097004-A1 | BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARβ) AGONISTS | KING'S COLLEGE LONDON (GB) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130337-A1 | Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists | RARB, RARA, RXRB | ACHE 1697/4885SELL 4341/4885SELP 4625/4885 |
| US-20170327489-A1 | Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists | RARB, RARA, RXRB | ACHE 1697/4885SELL 4341/4885SELP 4625/4885 |
| US-10385044-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | RARB, RARA, RARG | ACHE 1848/4885SELL 4389/4885SELP 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.